gdc
Breast CancerFDA NewsNewsworthy

Verzenio a New Targeted Therapy Approved for Metastatic Breast Cancer

Read about Verzenio, which was approved by the FDA in 2017, in combination with fulvestrant, for treatment of women with HR-positive, HER2-positive, HER2-negative advanced, or metastatic breast cancer that progressed after endocrine therapy.

December 2017 Vol 3 No 6

On September 28, 2017, the FDA approved Verzenio (abemaciclib; from Eli Lilly), a CDK4/CDK6 inhibitor, in combination with fulvestrant, for the treatment of women with HR-positive, HER2-negative advanced or metastatic breast cancer that progressed after endocrine therapy, as well as for use alone in patients whose metastatic breast cancer progressed after endocrine therapy and after previous use of chemotherapy in the metastatic setting.

“Verzenio provides a new targeted treatment option for certain patients with breast cancer who are not responding to treatment, and unlike other drugs in the class, it can be given as a stand-alone treatment to patients who were previously treated with endocrine therapy and chemotherapy,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence.

The FDA approved Verzenio for these 2 uses based on clinical trials showing its benefits for patients with HR-positive, HER2-negative advanced or metastatic breast cancer. The most common side effects with Verzenio are diarrhea, neutropenia, nausea, abdominal pain, infections, fatigue, anemia, leukopenia, decreased appetite, vomiting, headache, and thrombocytopenia.

Recommended For You
Breast Cancer
From Silent Voices to “Hear My Voice”: People Living with Metastatic Breast Cancer Are Speaking Out
By Martha Carlson, Catherine Ormerod
Advocacy program trains metastatic breast cancer patients to educate the public about the disease and helps them share resources with other patients.
Breast CancerCancer Biomarkers
What Are Biomarkers in Breast Cancer, and How Do They Affect My Treatment? – Interview with Daniel F. Hayes, MD, FACP, FASCO
In this interview, Dr. Daniel F. Hayes, MD, FACP, FASCO, Immediate Past President of ASCO and the Stuart B. Padno’s Professor of Breast Cancer Research at the University of Michigan Comprehensive Cancer Center talks about how biomarkers offer more precise treatment opportunities for breast cancer patients.
Cancer ScreeningFDA NewsNewsworthy
FDA Approves First Direct-to-Consumer Genetic Test for 3 Types of BRCA Mutations in Men and Women
By Dana Taylor
This first-ever direct-to-consumer genetic test can provide information on potential risks to individuals who may not have access to genetic screening, but the information may be misleading without feedback from experts.
Last modified: March 25, 2018

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country